NICE Rejects Novartis’ Xolair Use In Younger Children
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE’s analysis found that omalizumab was only useful in reducing the rate of clinically significant exacerbations in children with asthma who were having three of more exacerbations per year.